Chemours Company (The) (NYSE:CC) – Analysts at Jefferies Group raised their FY2018 earnings estimates for shares of Chemours Company (The) in a research report issued to clients and investors on Monday. Jefferies Group analyst L. Alexander now forecasts that the specialty chemicals company will post earnings of $5.35 per share for the year, up from their previous estimate of $5.15. Jefferies Group currently has a “Buy” rating and a $60.00 target price on the stock. Jefferies Group also issued estimates for Chemours Company (The)’s FY2019 earnings at $5.75 EPS and FY2020 earnings at $5.85 EPS.

Several other research firms also recently commented on CC. Zacks Investment Research upgraded Chemours Company (The) from a “hold” rating to a “buy” rating and set a $57.00 price objective for the company in a report on Thursday, November 9th. BidaskClub downgraded Chemours Company (The) from a “buy” rating to a “hold” rating in a report on Friday, August 11th. UBS AG boosted their price objective on Chemours Company (The) from $50.00 to $59.00 and gave the company a “neutral” rating in a report on Friday, November 3rd. Barclays PLC boosted their price objective on Chemours Company (The) from $55.00 to $58.00 and gave the company an “overweight” rating in a report on Monday, November 6th. Finally, Citigroup Inc. boosted their price objective on Chemours Company (The) from $45.00 to $59.00 and gave the company a “buy” rating in a report on Friday, August 4th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $53.89.

COPYRIGHT VIOLATION NOTICE: “FY2018 Earnings Estimate for Chemours Company (The) (CC) Issued By Jefferies Group” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/11/14/fy2018-earnings-estimate-for-chemours-company-the-cc-issued-by-jefferies-group.html.

Shares of Chemours Company (NYSE:CC) traded up $1.84 during mid-day trading on Tuesday, reaching $51.91. The company’s stock had a trading volume of 3,040,500 shares, compared to its average volume of 2,726,085. The company has a market capitalization of $9,380.00 and a P/E ratio of 17.75. The company has a debt-to-equity ratio of 5.07, a quick ratio of 1.63 and a current ratio of 2.19. Chemours Company has a 1-year low of $20.38 and a 1-year high of $58.08.

Chemours Company (The) (NYSE:CC) last issued its earnings results on Thursday, November 2nd. The specialty chemicals company reported $1.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.01 by $0.11. The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.59 billion. Chemours Company (The) had a return on equity of 116.80% and a net margin of 4.86%. The firm’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.61 earnings per share.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Monday, November 20th will be given a dividend of $0.03 per share. The ex-dividend date is Friday, November 17th. This represents a $0.12 annualized dividend and a dividend yield of 0.23%. Chemours Company (The)’s payout ratio is 8.28%.

In related news, SVP David C. Shelton sold 13,337 shares of Chemours Company (The) stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $48.48, for a total transaction of $646,577.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP David C. Shelton sold 19,000 shares of Chemours Company (The) stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $53.68, for a total value of $1,019,920.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 76,520 shares of company stock worth $4,008,293. 1.14% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in the stock. First Republic Investment Management Inc. purchased a new position in shares of Chemours Company (The) during the third quarter valued at approximately $203,000. Segall Bryant & Hamill LLC purchased a new position in shares of Chemours Company (The) during the third quarter valued at approximately $213,000. Magnetar Financial LLC boosted its position in shares of Chemours Company (The) by 119.9% during the third quarter. Magnetar Financial LLC now owns 17,614 shares of the specialty chemicals company’s stock valued at $891,000 after buying an additional 9,605 shares during the last quarter. Bell Bank purchased a new position in shares of Chemours Company (The) during the third quarter valued at approximately $202,000. Finally, Private Advisor Group LLC purchased a new position in shares of Chemours Company (The) during the third quarter valued at approximately $322,000. 72.90% of the stock is currently owned by institutional investors.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Earnings History and Estimates for Chemours Company (The) (NYSE:CC)

Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.